What Is The Difference Between A Hospital Formulary And A Preferred Supplier Agreement For Devices?

A hospital formulary and a preferred supplier agreement are two distinct tools in medical device procurement, and confusing them leads to budget overruns, inconsistent supply, and compliance headaches. A hospital formulary is an approved list of devices that clinical staff are authorized to use. A preferred supplier agreement is a commercial contract with a vendor that establishes pricing, terms, and supply conditions. Both shape purchasing decisions, but they operate at different levels of the procurement process.

Uncontrolled device purchasing is draining your procurement budget faster than you realize

When clinical departments order outside a structured formulary or supplier agreement, procurement loses visibility and control. Duplicate products from different vendors enter the supply chain, pricing becomes inconsistent, and volume discounts evaporate because spending is fragmented. The fix is not just tighter approval processes; it is building a clear framework in which the formulary defines what gets used and supplier agreements define who provides it and at what cost. Together, they close the gap that ad hoc purchasing leaves wide open.

Treating formularies and supplier agreements as the same tool is holding back your standardization goals

Many procurement directors apply one framework where two are needed. A formulary without a supplier agreement means approved products but no guaranteed pricing or supply continuity. A supplier agreement without a formulary means contracted vendors but no enforcement of what gets ordered at the point of care. When these two tools are conflated, standardization stalls, and clinicians end up using whichever product is available rather than what has been evaluated and approved. The concrete fix is to treat them as complementary layers: one governs clinical selection, the other governs commercial terms.

What is a hospital formulary for medical devices?

A hospital formulary for medical devices is an approved list of products that a hospital or health system has evaluated and authorized for clinical use. It defines which devices staff may order and use, based on clinical evidence, safety data, and cost-effectiveness. The formulary is maintained by a committee and updated as new products are assessed.

The formulary functions as a gatekeeping mechanism. Before a device reaches a clinician’s hands, it has gone through a review process that considers clinical performance, patient safety, compatibility with existing workflows, and total cost of use. This prevents departments from independently sourcing unvetted products and keeps procurement aligned with clinical governance standards.

Device formularies are common in larger hospital systems and NHS trusts, where standardization across departments and sites is a strategic priority. A well-maintained formulary reduces clinical variation, simplifies training, and gives procurement teams a defensible basis for consolidating spend with fewer suppliers.

What is a preferred supplier agreement for medical devices?

A preferred supplier agreement for medical devices is a formal contract between a hospital and a vendor that establishes the commercial terms under which the hospital will purchase products. These terms typically cover pricing, minimum order volumes, delivery timelines, service obligations, and the duration of the agreement. It does not automatically determine which products are clinically approved.

Preferred supplier agreements give procurement teams cost predictability and supply reliability. By committing a defined share of purchasing volume to a specific vendor, hospitals gain leverage to negotiate better pricing and service levels. In return, the supplier gains revenue certainty and a longer-term relationship with the institution.

These agreements are often structured at the health system or group purchasing level, meaning they can apply across multiple hospital sites. They may be tied to national frameworks, such as NHS Supply Chain in the UK, or negotiated directly between a hospital network and a manufacturer. The key point is that the agreement governs the commercial relationship, not the clinical decision about which product to use.

What’s the difference between a formulary and a preferred supplier agreement?

The core difference is scope and purpose. A formulary is a clinical governance tool that controls which devices are approved for use. A preferred supplier agreement is a commercial tool that controls how, and from whom, approved devices are purchased. The formulary answers “what can we use?” and the supplier agreement answers “who do we buy it from, and on what terms?”

In practice, the two tools work in sequence. A device must typically be on the formulary before a supplier agreement for that device makes sense. Once a product category is approved through the formulary process, procurement can negotiate a supplier agreement to lock in favorable terms for that category.

The distinction also matters for accountability. Clinical staff and medical committees typically govern the formulary. Procurement and finance teams govern supplier agreements. When these two groups are not aligned, hospitals end up with supplier agreements for products that are not on the formulary, or formulary-approved products that have no commercial framework behind them, creating unnecessary cost and supply risk.

How does a device get added to a hospital formulary?

A device is added to a hospital formulary through a formal evaluation process managed by a device committee or equivalent clinical governance body. The process typically involves a clinical needs assessment, product evaluation by end users, review of safety and performance data, cost analysis, and a committee vote or recommendation to approve the product for use.

The process usually begins when a clinician, department head, or supplier submits a request for a new product to be considered. The committee then reviews available evidence, which may include published clinical data, results from a controlled trial period, feedback from users at other institutions, and regulatory documentation such as CE marking or FDA clearance.

What role does cost play in formulary decisions?

Cost is always a factor, but it is evaluated as total cost of use rather than unit price alone. For single-use devices, this includes packaging, waste disposal, and procedural efficiency. For products replacing reusable alternatives, the comparison includes sterilization overhead, cross-contamination risk, and staff time. A product with a higher unit cost can still represent a net saving if it reduces procedural time or eliminates downstream costs.

Once approved, the device is added to the formulary with defined specifications, authorized sizes or configurations, and any restrictions on use. Departments are then expected to order only from the formulary unless an exception is formally requested and approved.

When should a hospital use a preferred supplier agreement instead of spot purchasing?

A hospital should use a preferred supplier agreement when a product category represents consistent, predictable demand and when supply continuity and price stability are priorities. Spot purchasing makes sense for low-volume, infrequent, or highly specialized needs. For high-frequency consumables used across multiple departments, a supplier agreement almost always delivers better value than repeated one-off orders.

Spot purchasing carries hidden costs that are easy to overlook. Each transaction requires administrative processing, price negotiation, and delivery coordination. When multiplied across hundreds of individual orders per year, the overhead adds up quickly. A supplier agreement consolidates this into a single negotiated framework, reducing transaction costs and freeing procurement staff to focus on higher-value activities.

There is also a supply continuity argument. A preferred supplier agreement gives the hospital priority in the vendor’s fulfillment queue and often includes guaranteed stock levels or lead-time commitments. During periods of supply disruption, hospitals with formal agreements are typically better positioned than those relying on spot market availability.

What are the most common mistakes in managing device formularies and supplier agreements?

The most common mistakes are letting formularies go stale, negotiating supplier agreements for products that have not been clinically evaluated, and failing to align procurement and clinical teams throughout the process. Each of these creates a different kind of operational and financial risk.

Formularies that are not regularly reviewed accumulate outdated products, while newer, better-performing options are blocked from entry. This frustrates clinicians who are aware of improved alternatives and creates pressure for off-formulary purchasing, which undermines the entire standardization effort.

Negotiating supplier agreements before completing clinical evaluation creates commercial commitments that may not be usable if the product fails the formulary review.
Failing to involve clinical end users in the evaluation process leads to formulary approvals that departments resist in practice, resulting in workarounds and maverick spend.
Setting supplier agreements without clear volume commitments weakens the hospital’s negotiating position and reduces the supplier’s incentive to offer competitive terms.
Not building a review cycle into supplier agreements means hospitals miss opportunities to renegotiate as the market evolves or as usage data becomes available.

The underlying issue in most cases is a disconnect between clinical governance and commercial procurement. When these two functions operate in silos, each makes decisions without full visibility into the other’s constraints. The hospitals that manage this best treat formulary management and supplier agreement negotiation as a joined-up process with shared ownership and regular communication between clinical and procurement stakeholders.

How Bridea Medical supports your formulary and supplier agreement process

When evaluating specula for your hospital formulary, we make the process straightforward. Our Orchid Specula are already used in 90% of Dutch hospitals and are listed on NHS Supply Chain frameworks in the UK, which means the clinical and commercial groundwork has already been done at scale.

Here is what we provide to support your evaluation and procurement process:

Clinical evidence and product documentation ready for formulary committee review, including performance data and regulatory certifications.
Flexible packaging formats including multi-pack, single-pack, and sterile options to match your department’s workflow and procurement requirements.
Consistent supply from our Netherlands production facility, supporting the reliability commitments that preferred supplier agreements depend on.

Whether you are adding specula to a formulary for the first time or reviewing an existing supplier agreement, we are ready to work with your procurement and clinical teams directly. Contact Bridea Medical to request product documentation, pricing frameworks, or a trial evaluation for your department. You can also explore the full Orchid Specula range or learn more about the Orchid Specula and what makes them the preferred choice for gynecology departments across Europe.

This content was generated with the help of AI and it may contain mistakes